Groth S, Tønnesen P, Asted M, Dirksen H, Sørensen P G
Eur J Clin Pharmacol. 1986;30(6):653-8. doi: 10.1007/BF00608211.
ICI 141,292 is a beta-blocker with beta 1-selective partial agonist activity. To study its cardioselectivity in humans, comparable beta-blocking doses of 200 mg ICI 141,292 and 100 mg atenolol were given to 12 patients with stable bronchial asthma. Both drugs significantly reduced the midexpiratory flow rate at 50% of vital capacity, whereas no significant reduction in FEV1 or peak expiratory flow rate were observed. It is concluded that the cardioselectivity of ICI 141,292 did not differ significantly from that of atenolol. Since they both had a measurable effect on respiratory mechanics, they should probably not be prescribed in bronchial asthma, or only with the greatest possible caution.
ICI 141,292是一种具有β1选择性部分激动剂活性的β受体阻滞剂。为研究其在人体中的心脏选择性，给12例稳定期支气管哮喘患者分别给予相当于200 mg ICI 141,292和100 mg阿替洛尔的β受体阻滞剂量。两种药物均显著降低了肺活量50%时的呼气中期流速，而第一秒用力呼气容积（FEV1）或呼气峰值流速未出现显著降低。得出结论，ICI 141,292的心脏选择性与阿替洛尔无显著差异。由于它们对呼吸力学均有可测量的影响，因此可能不应在支气管哮喘中使用，或仅在极其谨慎的情况下使用。
